Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Usability of CT-P47 subcutaneous auto-injector in rheumatoid arthritis
2022-002928-12Phase 3Completed
- Sponsor
- Celltrion
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Celltrion. Primary endpoint: Usability of CT-P47 auto-injector at Week 2. Started Nov 2022; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2022-002928-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002928-12.